Powered By Bing

Snyder Lab: Clinical

Currently, we are producing FDG and Methionine for routine clinical use. FDA is currently in preclinical setup phase in our lab, but will hopefully be moved to the clinic in the near future.  In addition, many others are being investigated as possibilities for clinical tracers at St. Jude.

[18F]2-fluoro-2-deoxy-D-glucose (18F-FDG)

FDG is the most commonly used radiotracer.  As a glucose analog, it tracks to sites of glucose utilization where it is metabolized and trapped.  As tumors are metabolically active, their need for glucose is higher than that of surrounding tissues.  Although quite useful in imaging cancers and also heart function, it also tracks to sites of inflammation so other tracers are useful to delineate more targeted processes.

L-[methyl-11C]Methionine (11C-MET)

As a C-11 labeled essential amino acid, 11C-MET is distributed by neutral amino acid transporters and is incorporated into proteins.  As it has little background uptake in the brain, but still crosses the blood brain barrier, it has been widely used in tumor detection in the brain and head and neck, as well as lung, breast, and lymphomas.  St. Jude is currently conducting a clinical trial for the use of MET in solid tumors in children.

6-[18F]Fluorodopamine (6-[18F]FDA)

6-[18F]FDA is taken up into sympathetic nerve terminals where it is converted to of 6-[18F]Fluoronorepinephrine.  Originally used for PET imaging in the heart, more intense signals would be observed from sympathetically innervated tissues than noninnervated tissues.  More recently, studies have shown 6-[18F]FDA as a candidate for imaging  neuroendocrine tumors, such as pheochromocytomas and neuroblastoma.